Elsevier

Leukemia Research

Volume 25, Issue 3, March 2001, Pages 221-225
Leukemia Research

MUC1 expression in plasmacytoma

https://doi.org/10.1016/S0145-2126(00)00111-9Get rights and content

Abstract

Plasmacytoma (Pm) is a plasma cell (PC) neoplasia consisting of PCs and some of them show progression to multiple myeloma. But there is no clear indicators predicting this progression. In this study, MUC1 expression was evaluated in Pm cases to determine the predictive value and was compared with histopathologic grade which is known to be a prognostic indicator in Pm. Nine of 31 cases with Pm showed MUC1 expression. Only two of the 18 cases with mature morphology showed MUC1 expression while seven of 13 cases with immature morphology showed MUC1 expression and this was statistically significant (P < 0.006). Additionally, four of 11 cases with BM involvement showed MUC1 expression while five of 20 cases without BM involvement showed MUC1 expression. There was a trend MUC1 expression with BM involvement but there was not statistically significant association between MUC1 expression and BM involvement. We found that MUC1 expression is associated with immature morphology which is an important prognostic indicator in Pm and by analogy MUC1 expression may be an additional prognostic indicator in patients with Pm.

Introduction

Plasmacytomas (Pm) are relatively uncommon plasma cell (PC) neoplasias that may arise in a variety of soft tissues and bone. Some of them show progression to multiple myeloma (MM), while others tend to be localized, but there are no clear indicators predicting the progression to the MM [1], [2].

Mucins are glycoproteins with high molecular weight, produced by ductal epithelial cells of a variety of tissues and also by tumors deriving from these tissues [3]. To date, at least eight mucin genes encoding the protein backbone of these glycoproteins have been identified. Of these mucins, MUC1 codes for the membrane-bound mucin [4], [5], [6], [7]. MUC1 mucin is secreted by normal and malignant epithelial cells and is thought to function through cell–cell interactions and transmembrane signal transduction events [8]. MUC1 disturbs cell–cell interaction, inhibits aggregation in vitro, and decreases the activity of natural killer cells and lymphokine activated killer cells in cancer tissues. Cancer cells expressing high levels of MUC1 may be able to detach from the primary tumor and survive in circulation or in distant organs by escaping from immune surveillance [9], [10], [11]. MUC1 is frequently overexpressed in various human tumors: including the carcinoma of the breast, colon, rectum, stomach, kidney, pancreas, bile duct and ovary, and generally a poor prognostic indicator in these tumors [5], [6], [9], [10], [12], [13], [14], [15], [16]. By analogy with these malignant tumors MUC1 expression in Pm was evaluated in this study to determine whether it is a progression marker in Pm.

Section snippets

Materials and methods

The material used in this study consisted of 35 samples taken from 31 cases. Age range was between 19 and 71; 14 of them were female and 17 were male. In eight cases, Pm was originated from soft tissues and rest of them were Pm of the bone origin. In 12 cases Pm accompanied the MM. Complete blood count, erythrocyte sedimentation rate, total protein/albumin, protein and immune electrophoresis and renal function tests, skeletal surveys were done in all cases. BM aspiration and biopsy samples and

Results

Thirty five Pm samples taken from 31 cases were evaluated in this study for MUC1 expression. Totally, ten samples belonging to nine cases showed MUC1 expression (9/31 = 29%). There was (+) MUC1 staining in three and (+ +) staining in six cases. Fig. 1a and Fig. 1b show the (+) and (+ +) MUC1 expression. Clinical presentation, BM involvement status, histopathologic grade and MUC1 expression were summarized in Table 1. Histopathologically Pm was mature in 18 cases and immature in 13 cases. The

Discussion

Pms are relatively uncommon PC neoplasias and are mainly divided into two groups: extramedullary Pm (EMP) and solitary bone Pm (SBP). Biologically they have different clinical outcome. EMPs tend to be localized and it has been suggested that biological behavior looks like marginal zone lymphoma [1]. SBPs involve most commonly to the axial skeleton and at least 50% show progression to the MM. Both EMPs and SBPs may progress to MM, and there are no clear prognostic indicators, accepted for all

Acknowledgements

This study has been supported by Çukurova University Research Fund. We thank Prof Dr Refik Burgut due to his statistical support.

References (23)

  • B Agrawal et al.

    Expression of MUC1 mucin on activated human T cells: implications for a role of MUC1 in normal immune regulation

    Cancer Res

    (1998)
  • Cited by (20)

    • MUC1-C drives MYC in multiple myeloma

      2016, Blood
      Citation Excerpt :

      Consistent with these results, we also found a significant correlation between MUC1 and MYC in primary MM cells when analyzing the GSE26760 data set (n = 304) (Figure 6E), supporting the notion that MUC1-C upregulates MYC expression. MUC1-C is aberrantly expressed in most primary MM patient samples and cell lines, but not normal B-lineage cells.13-18 In addition, the WNT/β-catenin pathway is activated in MM and is a potential target for the treatment of MM.57-59

    • Inhibition of the MUC1-C oncoprotein induces multiple myeloma cell death by down-regulating TIGAR expression and depleting NADPH

      2012, Blood
      Citation Excerpt :

      However, invariably, patients eventually relapse and succumb to this disease, emphasizing the need for additional therapeutic targets. Mucin 1 (MUC1) is a heterodimeric protein that is aberrantly expressed in most multiple myeloma cell lines and primary patient samples.2-8 The extracellular MUC1 N-terminal subunit (MUC1-N) contains glycosylated tandem repeats that are a characteristic of mucin family members.9

    • Increased cancer antigen 27.29 (CA27.29) level in patients with mycosis fungoides

      2008, Journal of the American Academy of Dermatology
      Citation Excerpt :

      In the third patient, serial blood samples were not drawn. Patients with other hematologic malignancies, including acute myelogenous leukemia and plasma cell dyscrasias, have also demonstrated elevated sMUC1 levels.12-14 Using an FDA-cleared immunoassay that recognizes the CA27.29 MUC1 epitope, Treon et al15 reported that sMUC1 levels were elevated in both bone marrow and peripheral blood plasma of patients with multiple myeloma compared with levels in healthy donors.

    • Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma

      2006, Experimental Hematology
      Citation Excerpt :

      An explanation could be a deletion of the antitumor Ig T cell clones in patients with MM due to the high levels of circulating tumor Ig lasting for several years in the premalignant stage of the disease. Other antigens, such as MAGE, Sperm-17, or the MUC1 core protein are expressed on only a part of myeloma cells from a subset of patients [13,15,32,33]. In contrast HM1.24 is found on >90% of primary myeloma cells [18].

    View all citing articles on Scopus
    View full text